Cancer name Non Small Cell Lung Cancer
Cancer Type NSCLC
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment SAR
Drugstatus Approved;Investigated
Drugbank ID DB12500
Checkpoints NA
Signature Type Protein
Signature PD-L1
Official Symbol CD274
Mode of action PROT_D_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental Cell lines
Description The addition of SAR significantly suppressed IFN-inducible PD-L1 expression in all NSCLC cell lines. SAR also decreased basal PD-L1 expression, which was measurable in 2 of 6 cell lines. Taken together, these data demonstrated that SAR decreases basal and IFN-gamma-inducible PD-L1 expression in tumor cells in human and murine models of lung carcinoma.
PMID 29467274
Title JAK2 Inhibitor SAR302503 Abrogate sPD-L1 Expression and Targets Therapy Resistant Non–small Cell Lung Cancers